Urbagen gene addition therapy (CTNNB1 Foundation)

N/A

Report date: 2025/12/10 20:01:13
NME

Base Information

Drug NameUrbagen gene addition therapy (CTNNB1 Foundation)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV9 vector
Mechanisms of ActionCatenin beta 1 modulators
TargetsCatenin beta 1
Therapy Area/IndicationsNeurodevelopmental Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySlovenia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCTNNB1 Foundation
China Registration ClassN/A

Develop Information

Active CompaniesCTNNB1 Foundation
Inactive CompaniesN/A
Active IndicationsNeurodevelopmental Disorders
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A